How emerging investment models are rewiring biotech funding structures for efforts in rare disease.
Casey McPherson
Advertisement
Casey McPherson, founder and CEO, AlphaRose Therapeutics.
Articles by Casey McPherson
Advertisement
Latest Updated Articles
The New Capital of Care in Rare DiseaseJune 10th 2026
Advertisement
Advertisement
Trending on PharmExec
1
Where Does Boehringer Ingelheim Stand Between Oral or Injectable GLP-1’s Being The Future of Obesity Care?
2
FDA Files Concerns Over Missing Data for Moderna’s mRNA Flu Shot: Report
3
How Behavioral and Engagement Insights Improve Persistence in Patient Support Programs
4
The Industry's Interest in Vaccine Platforms
5